PORTFOLIO

PORTFOLIO COMPANIES

MOLCURE Inc.

  • CEO, Co-founder:
    Ryu Ogawa

URL:http://molcure.com/

COMPANY PROFILE

High-functional antibody drug development platform based on next generation sequencing and bioinformatics

MOLCURE is a high quality antibody and target discovery startup. MOLCURE combines a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. MOLCURE's proprietary antibody discovery platform AbtracerTM delivers superior functional antibodies by removing library and selection bias.

COMPANY STORY

Origin

Ryu Ogawa, the founder of Molcure, was striving to become a scientist at Keio University when he lost his father to cancer. This motivated him to establish a startup that enables the quickest way to make drugs by making full use of scientific advancements to develop drug for cancer.

Strength

The company has developed a drug discovery platform that enables them to acquire highly-
functional antibodies from antibody libraries which was unable to detect by the conventional methods by combining the conventional method for preparing antibodies with next generation sequencers and machine learning.

UTEC value up

Multifaceted support such as accelerating the business through funding, introducing collaborators with high technology-related synergies, designing business strategies and introducing customers.
  • Proprietary antibody development platform : Abtracer.

RELATED NEWS